Amylyx Pharmaceuticals Inc (AMLX)vsUnited Therapeutics Corporation (UTHR)
AMLX
Amylyx Pharmaceuticals Inc
$29.86
-6.10%
HEALTHCARE · Cap: $4.09B
UTHR
United Therapeutics Corporation
$593.31
-0.39%
HEALTHCARE · Cap: $25.07B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates -479423% more annual revenue ($3.19B vs $-665,000). UTHR leads profitability with a 38.6% profit margin vs 0.0%. UTHR earns a higher WallStSmart Score of 55/100 (C).
AMLX
Avoid33
out of 100
Grade: F
UTHR
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AMLX.
Margin of Safety
+2.4%
Fair Value
$487.71
Current Price
$593.31
$105.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 39 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.0%
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Expensive relative to growth rate
4.1% revenue growth
Earnings declined 20.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Altman Z-Score, Operating Margin. Profitability is solid with margins at 38.6% and operating margin at 29.0%.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Profit Margin, Operating Margin.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
UTHR carries more volatility with a beta of 0.48 — expect wider price swings.
UTHR is growing revenue faster at 4.1% — sustainability is the question.
UTHR generates stronger free cash flow (126M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
UTHR scores higher overall (55/100 vs 33/100), backed by strong 38.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is an innovative biopharmaceutical company at the forefront of developing transformative therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). The company's lead candidate, AMX0035, employs a unique neuroprotective mechanism that has shown significant potential in improving patient outcomes in clinical trials. With a robust pipeline and a dedicated team of neurology experts, Amylyx is well-positioned to tackle substantial unmet medical needs in the neurodegenerative space, making it an attractive investment opportunity for institutional investors seeking to support advancements in critical healthcare solutions.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?